Test Price
2,800 AED✅ Home Collection Available
UAE Genetic Health Authority – Trusted Partnership
PCDH15 Gene Sequencing (Autosomal Recessive Deafness Type 23, NGS) in UAE | AED 2,800 | 2026 DHA Guidelines
تحليل جين PCDH15 للصمم الوراثي المتنحي من النوع 23 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection using ISO-Certified Cold-Chain transport and VIP Mobile Phlebotomy (8 AM – 11 PM).
- Clinical Guidance: Telephonic post-test clinical guidance for result interpretation with a DHA-licensed genetic counselor.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
- UAE Legal Compliance: Operates under Federal Decree-Law No. 41 of 2024 Art. 87, CDS Law 2026 (Minors), and UAE PDPL.
نضمن دقة تشخيصية بنسبة ٩٩.٩٪ عبر فحص جيني متطور ومعتمد من ISO. نقدم خدمة سحب الدم المنزلي بمعايير المستشفى مع سلسلة تبريد دولية. استشارة طبية هاتفية بعد النتائج. تحقق من تغطية التأمين عبر واتساب.
Overview
This test analyses the PCDH15 gene using Next-Generation Sequencing (NGS) to detect mutations causing autosomal recessive deafness type 23 (DFNB23), a severe-to-profound congenital hearing loss. Pre-test genetic counseling is mandatory, and sample types accepted are Blood, Extracted DNA, or one drop of blood on an FTA card. هذا التحليل الجيني لجين PCDH15 بتقنية التسلسل عالي الإنتاجية (NGS) يكشف الطفرات المسببة للصمم الوراثي المتنحي من النوع 23، مما يوفر تشخيصًا مبكرًا ويوجه خيارات العلاج مثل القوقعة. تُقبل عينات الدم أو الحمض النووي المستخلص أو بطاقة FTA.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Method | NGS (Full Gene Sequencing) | Sanger Sequencing (Single Variant) |
| Diagnostic Yield | >98% for DFNB23 | ~60% (targeted only) |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks (limited scope) |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY, DHA License No. 61713011, Consultant ENT & Genetics, shares: “The PCDH15 NGS test provides a definitive molecular diagnosis for DFNB23, guiding cochlear implant candidacy and family planning. However, genetic results must always be interpreted within the full clinical context, considering audiological and vestibular assessments.”
Medication Warning
Do not discontinue prescribed medication without consulting your doctor. This genetic test is for diagnostic clarification only and does not alter ongoing otological or neurological treatments.
Patient Safety & Exclusion Criteria
- Not for acute sudden sensorineural hearing loss—seek emergency ENT evaluation.
- Minors require parental/legal guardian consent as per UAE CDS Law 2026.
- Individuals with active ear infections or recent ear surgery should postpone sample collection.
- If result interpretation suggests a syndromic form (e.g., Usher syndrome), urgent ophthalmology referral is warranted—inform the lab immediately.
Patient FAQ & Clinical Guidance
1. What is the PCDH15 gene test and who should consider it?
The PCDH15 NGS test diagnoses autosomal recessive deafness type 23 for early cochlear implant planning. This comprehensive analysis pinpoints the exact mutation, confirms inheritance pattern, and empowers clinicians to tailor hearing rehabilitation and genetic counseling. يكشف اختبار جين PCDH15 الطفرات المسببة للصمم الوراثي المتنحي ٢٣ لتأكيد التشخيص وتوجيه العلاج.
2. How accurate is the NGS methodology for this hearing loss gene?
Our NGS detects all PCDH15 mutations with 99.9% sensitivity, surpassing single-gene screening for hereditary deafness diagnosis. The technology reads the full gene coding region, uncovering even rare or novel variants missed by conventional methods. بدقة ٩٩.٩٪ وتغطية كاملة للإكسونات، يتفوق اختبارنا على فحوصات الجين الواحد.
3. What sample is required and how long do results take?
A blood or DNA FTA card sample delivers NGS results within 3-4 weeks. This timeline includes full sequencing, bioinformatics analysis, and a detailed clinical report reviewed by our DHA-licensed genetics team. كل ما يلزم هو عينة دم بسيطة أو حمض نووي على بطاقة FTA؛ تُصدر النتائج خلال ٣-٤ أسابيع.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians